title: Impact of TTV and SENV infection in chronic hepatitis B or C on liver histology and therapy outcome.
abstract: OBJECTIVE
  To determine the influence of TTV and SENV on histological findings and viral response in patients with chronic viral hepatitis B and C.
  
  
  BACKGROUND
  The clinical impact of TTV or SENV coinfections in these patients remains unclear.
  
  
  METHODS
  Serum and liver biopsy specimens from chronic hepatitis B and C patients, 107 with liver biopsy and 105 who had finished complete antiviral therapy, were investigated for the presence of TTV and SENV.
  
  
  RESULTS
  The Ishak score determined from 107 liver biopsy samples compared according to TTV or SENV coinfection was similar. Among 39 chronic hepatitis C patients with and 43 without virological response, we have found 9 and 3 SENV positive (p < 0.05) and 18 and 28 TTV positive patients, respectively (not significant). However 11 of 32 biopsy samples obtained in the responder's group and 19 of 31 in non-responders were TTV positive (p < 0.05). No similar differences were observed among 23 chronic hepatitis B patients. TTV clearance after interferon therapy exceeded 80%, clearance of SENV 90%.
  
  
  CONCLUSIONS
  TTV or SENV infections did not negatively influence the severity of histological features or the antiviral response in patients with chronic hepatitis B and C. Both viruses were highly sensitive to interferon therapy (Tab. 5, Ref. 29).
authors.affiliation: Department of Infectology and Travel Medicine, Faculty ofMedicine, P. J. Safarik University, Kosice, Slovakia. kristian@fnlp.sk
authors.forename: P
authors.initials: P
authors.lastname: Kristian
authors.forename: I
authors.initials: I
authors.lastname: Schreter
authors.forename: L
authors.initials: L
authors.lastname: Siegfried
authors.forename: P
authors.initials: P
authors.lastname: Jarcuska
authors.forename: P
authors.initials: P
authors.lastname: Jarcuska
authors.forename: Z
authors.initials: Z
authors.lastname: Paralicova
authors.forename: S
authors.initials: S
authors.lastname: Porubcin
mesh_terms: D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use; D004266:DNA Virus Infections / Q000150:complications* / Q000473:pathology; D005260:Female; D019694:Hepatitis B, Chronic / Q000150:complications* / Q000188:drug therapy / Q000473:pathology; D019698:Hepatitis C, Chronic / Q000150:complications* / Q000188:drug therapy / Q000473:pathology; D006801:Humans; D008099:Liver / Q000473:pathology*; D008297:Male; D022783:Torque teno virus / Q000302:isolation & purification; D016896:Treatment Outcome
chemical_list: D000998:Antiviral Agents